Funding co-led by Inovia Capital and Tola Capital brings AI-powered software to the biopharmaceutical industry with first product Reliant Tabular
Reliable AIa provider of AI-powered data analytics software, has quietly announced its launch with $11.3 million in seed funding. The new capital was co-led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi.
Reliant AI was founded by Karl Moritz Hermann, Marc Bellemare and Richard Schlegel, leading scientists and researchers in natural language processing and reinforcement learning who have led teams at DeepMind, Google Brain and EY Parthenon. They are passionate about how generative AI can solve information problems to reduce repetitive mental work and accelerate decision-making for businesses. The company is initially targeting the biopharmaceutical sector and will use the new funding to hire talented engineers to expand its technology investments and presence in Europe and North America.
“Information and data are a largely overlooked element in the advancements of life sciences to create a better world. The sheer amount of menial labor involved in today’s data-intensive industries means that many highly skilled professionals are focused on managing data, rather than solving complex problems. We’ve created an AI system that understands life sciences to radically increase its ability to perform research at scale,” said Karl Moritz Hermann, CEO and co-founder of Reliant AI.
Reliant AI’s first product, Connecting Tableis an AI tool that is gaining significant traction across major segments of the biopharmaceutical industry. The product helps life sciences analysts find scientific evidence to support their decisions through automated systematic reviews, asset analyses, comprehensive analytics, and a customizable data platform. With Reliant AI, everything can be queried.
Reliant Tabular features include:
- Proprietary ML models optimized to be experts in biopharmaceutical topics
- Comprehensive approach to fact-finding – maximize recall so you don’t forget anything
- User interface that allows to quickly and easily reconcile the generated results with the basic evidence
- Responses in a report-ready format so teams can collaborate on analytics
“The biopharmaceutical industry has a massive and underserved need for information. Reliant AI combines cutting-edge research and domain expertise to create software that can process a day’s worth of data in 30 seconds. Marc, Karl Moritz and their technical team bring together decades of AI expertise from the world’s top research groups, such as DeepMind, Google Brain and Meta, giving Reliant the ability to truly advance the application of generative AI to real-world data problems,” said Aaron Fleishman, Partner at Tola Capital.
“We see significant market opportunity in the pharmaceutical sector as companies strive to create and partner with new players to develop innovative solutions like those offered by Reliant AI,” said Steve Woods, Partner at Inovia Capital. “This significant demand in a large and growing market underscores the potential for AI to drive significant advancements in the biopharmaceutical industry.”
“Reliant AI has dramatically increased my efficiency by quickly analyzing relevant data, allowing me to focus on deeper analyses and faster turnaround times. This technology promises to revolutionize how early commercial evaluations are conducted,” said Miguel Silva, Chief Strategy Officer at OMass Therapeutics.
Subscribe to insideAI news for free newsletter.
Join us on Twitter: https://twitter.com/InsideBigData1
Join us on LinkedIn: https://www.linkedin.com/company/insideainews/
Join us on Facebook: https://www.facebook.com/insideAINEWSNOW
